Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.

Animals Antibodies, Monoclonal / immunology Antibodies, Neutralizing / immunology Antibodies, Viral / immunology Antigen-Antibody Complex / chemistry COVID-19 / pathology COVID-19 Vaccines / administration & dosage Chlorocebus aethiops Crystallography, X-Ray Humans Immunization, Passive Neutralization Tests Protein Domains / immunology SARS-CoV-2 / genetics Spike Glycoprotein, Coronavirus / chemistry Vero Cells COVID-19 Serotherapy
B.1.617 Delta variant Receptor-binding-domain SARS-CoV-2 antibody escape neutralization structure vaccine variant

Journal

Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066

Informations de publication

Date de publication:
05 08 2021
Historique:
received: 25 05 2021
revised: 04 06 2021
accepted: 11 06 2021
pubmed: 10 7 2021
medline: 20 8 2021
entrez: 9 7 2021
Statut: ppublish

Résumé

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive change, with variants conferring advantage rapidly becoming dominant lineages, e.g., B.1.617. With apparent increased transmissibility, variant B.1.617.2 has contributed to the current wave of infection ravaging the Indian subcontinent and has been designated a variant of concern in the United Kingdom. Here we study the ability of monoclonal antibodies and convalescent and vaccine sera to neutralize B.1.617.1 and B.1.617.2, complement this with structural analyses of Fab/receptor binding domain (RBD) complexes, and map the antigenic space of current variants. Neutralization of both viruses is reduced compared with ancestral Wuhan-related strains, but there is no evidence of widespread antibody escape as seen with B.1.351. However, B.1.351 and P.1 sera showed markedly more reduction in neutralization of B.1.617.2, suggesting that individuals infected previously by these variants may be more susceptible to reinfection by B.1.617.2. This observation provides important new insights for immunization policy with future variant vaccines in non-immune populations.

Identifiants

DOI: 10.1016/j.cell.2021.06.020 PMID: 34242578 PMC: PMC8218332
pubmed: 34242578
pii: S0092-8674(21)00755-8
doi: 10.1016/j.cell.2021.06.020
pmc: PMC8218332
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antibodies, Neutralizing 0
Antibodies, Viral 0
Antigen-Antibody Complex 0
COVID-19 Vaccines 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4220-4236.e13

Subventions

Organisme : Wellcome Trust
ID : 203224/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V028448/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00008/11
Pays : United Kingdom
Organisme : Bill & Melinda Gates Foundation
ID : INV-016202
Pays : United States
Organisme : Medical Research Council
ID : MR/N00065X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V001329/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19060
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_20016
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 109965/Z/15/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L018942/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0600520
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1001046
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19055
Pays : United Kingdom

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests G.R.S. is on the GSK Vaccines Scientific Advisory Board. Oxford University holds intellectual property related to the Oxford-AstraZeneca vaccine. A.J.P. is Chair of UK Department Health and Social Care’s (DHSC) Joint Committee on Vaccination & Immunisation (JCVI) but does not participate in the JCVI COVID19 committee and is a member of the WHO’s SAGE. The views expressed in this article do not necessarily represent the views of DHSC, JCVI, or WHO. The University of Oxford has entered into a partnership with AstraZeneca on coronavirus vaccine development. The University of Oxford has protected intellectual property disclosed in this publication. S.C.G. is co-founder of Vaccitech (collaborators in the early development of this vaccine candidate) and is named as an inventor on a patent covering use of ChAdOx1-vectored vaccines and a patent application covering this SARS-CoV-2 vaccine (PCT/GB2012/000467). T.L. is named as an inventor on a patent application covering this SARS-CoV-2 vaccine and was a consultant to Vaccitech for an unrelated project during the conduct of the study.

Références

Bio Protoc. 2021 Nov 05;11(21):e4236
pubmed: 34859134
Science. 2004 Jul 16;305(5682):371-6
pubmed: 15218094
Cell Host Microbe. 2021 May 12;29(5):819-833.e7
pubmed: 33789084
J Mol Biol. 2007 Sep 21;372(3):774-97
pubmed: 17681537
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Acta Crystallogr D Struct Biol. 2018 Feb 1;74(Pt 2):85-97
pubmed: 29533234
Cell. 2021 May 27;184(11):2939-2954.e9
pubmed: 33852911
Science. 2020 Aug 28;369(6507):1119-1123
pubmed: 32661058
Acta Crystallogr D Struct Biol. 2020 Nov 1;76(Pt 11):1134-1144
pubmed: 33135684
Lancet Microbe. 2020 Jul;1(3):e99-e100
pubmed: 32835336
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Med J Aust. 2020 Jun;212(10):459-462
pubmed: 32237278
Cell. 2021 Jun 24;184(13):3426-3437.e8
pubmed: 33991487
Nat Commun. 2020 Sep 1;11(1):4376
pubmed: 32873808
Science. 2021 Aug 6;373(6555):648-654
pubmed: 34210893
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Cell. 2021 Jan 7;184(1):64-75.e11
pubmed: 33275900
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Acta Crystallogr D Biol Crystallogr. 2006 Oct;62(Pt 10):1243-50
pubmed: 17001101
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
Mol Cell. 2020 Sep 3;79(5):710-727
pubmed: 32853546
Cell. 2020 Nov 12;183(4):1058-1069.e19
pubmed: 33058755
Cell. 2021 Apr 15;184(8):2183-2200.e22
pubmed: 33756110
Science. 2020 Aug 21;369(6506):1014-1018
pubmed: 32540904
Science. 2014 Nov 21;346(6212):996-1000
pubmed: 25414313
Cell. 2021 Apr 29;184(9):2348-2361.e6
pubmed: 33730597
Nat Commun. 2021 Jan 20;12(1):469
pubmed: 33473140
Microbiol Mol Biol Rev. 2012 Jun;76(2):159-216
pubmed: 22688811
Cell. 2021 Apr 15;184(8):2201-2211.e7
pubmed: 33743891
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
J Mol Biol. 1979 Oct 15;134(1):109-42
pubmed: 537059
Acta Crystallogr D Struct Biol. 2019 Oct 1;75(Pt 10):861-877
pubmed: 31588918
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
Emerg Microbes Infect. 2020 Dec;9(1):680-686
pubmed: 32207377
Lancet. 2021 Dec 19;396(10267):1979-1993
pubmed: 33220855
Protein Expr Purif. 2008 Nov;62(1):83-9
pubmed: 18662785
N Engl J Med. 2021 May 20;384(20):1899-1909
pubmed: 33951374
Nat Med. 2021 Mar;27(3):440-446
pubmed: 33531709
Nature. 2021 Apr;592(7853):277-282
pubmed: 33545711
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
RNA. 2003 Apr;9(4):493-501
pubmed: 12649500
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Lancet. 2021 Apr 10;397(10282):1351-1362
pubmed: 33798499
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Nature. 2021 May;593(7857):130-135
pubmed: 33684923

Auteurs

Chang Liu (C)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.

Helen M Ginn (HM)

Diamond Light Source Ltd., Harwell Science & Innovation Campus, Didcot, UK.

Wanwisa Dejnirattisai (W)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Piyada Supasa (P)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Beibei Wang (B)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Aekkachai Tuekprakhon (A)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Rungtiwa Nutalai (R)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Daming Zhou (D)

Division of Structural Biology, The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Alexander J Mentzer (AJ)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Yuguang Zhao (Y)

Division of Structural Biology, The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Helen M E Duyvesteyn (HME)

Division of Structural Biology, The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

César López-Camacho (C)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Jose Slon-Campos (J)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Thomas S Walter (TS)

Division of Structural Biology, The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Donal Skelly (D)

Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Sile Ann Johnson (SA)

Peter Medawar Building for Pathogen Research, Oxford, UK.

Thomas G Ritter (TG)

Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Chris Mason (C)

Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Sue Ann Costa Clemens (SA)

Institute of Global Health, University of Siena, Siena, Brazil; Department of Paediatrics, University of Oxford, Oxford, UK.

Felipe Gomes Naveca (F)

Laboratório de Ecologia de Doenças Transmissíveis na Amazônia, Instituto Leônidas e Maria Deane, Fiocruz, Manaus, Amazonas, Brazil.

Valdinete Nascimento (V)

Laboratório de Ecologia de Doenças Transmissíveis na Amazônia, Instituto Leônidas e Maria Deane, Fiocruz, Manaus, Amazonas, Brazil.

Fernanda Nascimento (F)

Laboratório de Ecologia de Doenças Transmissíveis na Amazônia, Instituto Leônidas e Maria Deane, Fiocruz, Manaus, Amazonas, Brazil.

Cristiano Fernandes da Costa (C)

Fundação de Vigilância em Saúde do Amazonas, Manaus, Amazonas, Brazil.

Paola Cristina Resende (PC)

Laboratorio de vírus respiratórios-IOC/FIOCRUZ, Rio de Janeiro, Brazil.

Alex Pauvolid-Correa (A)

Laboratorio de vírus respiratórios-IOC/FIOCRUZ, Rio de Janeiro, Brazil; Department of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX, USA.

Marilda M Siqueira (MM)

Laboratorio de vírus respiratórios-IOC/FIOCRUZ, Rio de Janeiro, Brazil.

Christina Dold (C)

NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.

Nigel Temperton (N)

Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent and Greenwich, Chatham Maritime, Kent ME4 4TB, UK.

Tao Dong (T)

Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

Andrew J Pollard (AJ)

NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.

Julian C Knight (JC)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Derrick Crook (D)

Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Teresa Lambe (T)

Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Elizabeth Clutterbuck (E)

NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.

Sagida Bibi (S)

NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.

Amy Flaxman (A)

Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Mustapha Bittaye (M)

Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Sandra Belij-Rammerstorfer (S)

Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Sarah C Gilbert (SC)

Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Tariq Malik (T)

National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.

Miles W Carroll (MW)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.

Paul Klenerman (P)

Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; Translational Gastroenterology Unit, University of Oxford, Oxford, UK.

Eleanor Barnes (E)

Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; Translational Gastroenterology Unit, University of Oxford, Oxford, UK.

Susanna J Dunachie (SJ)

Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Centre For Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand; Department of Medicine, University of Oxford, Oxford, UK.

Vicky Baillie (V)

South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Natali Serafin (N)

South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Zanele Ditse (Z)

South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Kelly Da Silva (K)

South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Neil G Paterson (NG)

Diamond Light Source Ltd., Harwell Science & Innovation Campus, Didcot, UK.

Mark A Williams (MA)

Diamond Light Source Ltd., Harwell Science & Innovation Campus, Didcot, UK.

David R Hall (DR)

Diamond Light Source Ltd., Harwell Science & Innovation Campus, Didcot, UK.

Shabir Madhi (S)

South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Marta C Nunes (MC)

South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Philip Goulder (P)

Peter Medawar Building for Pathogen Research, Oxford, UK; Department of Paediatrics, University of Oxford, Oxford, UK.

Elizabeth E Fry (EE)

Division of Structural Biology, The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Juthathip Mongkolsapaya (J)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Siriraj Center of Research Excellence in Dengue & Emerging Pathogens, Dean Office for Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand. Electronic address: jmongkol@well.ox.ac.uk.

Jingshan Ren (J)

Division of Structural Biology, The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Electronic address: ren@strubi.ox.ac.uk.

David I Stuart (DI)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Diamond Light Source Ltd., Harwell Science & Innovation Campus, Didcot, UK; Division of Structural Biology, The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Instruct-ERIC, Oxford House, Parkway Court, John Smith Drive, Oxford, UK. Electronic address: dave@strubi.ox.ac.uk.

Gavin R Screaton (GR)

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK. Electronic address: gavin.screaton@medsci.ox.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Reduced neutralization of SARS-CoV-2 B.1.617...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Reduced neutralization of SARS-CoV-2 B.1.617...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › Reduced neutralization of SARS-CoV-2 B.1.617...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Reduced neutralization of SARS-CoV-2 B.1.617...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Complexe antigène-anticorps › Reduced neutralization of SARS-CoV-2 B.1.617...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Reduced neutralization of SARS-CoV-2 B.1.617...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre la COVID-19 › Reduced neutralization of SARS-CoV-2 B.1.617...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Cercopithecidae › Cercopithecinae › Cercopithecus › Cercopithecus aethiops › Reduced neutralization of SARS-CoV-2 B.1.617...
questionsmedicales.fr › Techniques d'investigation › Techniques de chimie analytique › Cristallographie aux rayons X › Reduced neutralization of SARS-CoV-2 B.1.617...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Reduced neutralization of SARS-CoV-2 B.1.617...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunisation passive › Reduced neutralization of SARS-CoV-2 B.1.617...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Tests immunologiques › Tests sérologiques › Tests de neutralisation › Reduced neutralization of SARS-CoV-2 B.1.617...
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Conformation moléculaire › Conformation des protéines › Structure tertiaire des protéines › Domaines protéiques › Reduced neutralization of SARS-CoV-2 B.1.617...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Reduced neutralization of SARS-CoV-2 B.1.617...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines virales › Protéines virales structurales › Protéines de l'enveloppe virale › Protéines de fusion virale › Glycoprotéine de spicule des coronavirus › Reduced neutralization of SARS-CoV-2 B.1.617...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules Vero › Reduced neutralization of SARS-CoV-2 B.1.617...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunisation passive › Transfert adoptif › Sérothérapie COVID-19 › Reduced neutralization of SARS-CoV-2 B.1.617...